Indivior Pharmaceuticals, Inc. (INDV) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Indivior's earnings call highlights strong financial performance, with SUBLOCADE revenue growth and improved cash flow, despite a significant DOJ payment. Optimistic guidance for 2025 and a focus on shareholder returns through share repurchases are positive indicators. While management avoided some specifics, the overall sentiment in the Q&A was positive, with analysts recognizing growth potential in LAI buprenorphine penetration. The company's strategic focus on new therapeutic areas and operational efficiencies further supports a positive outlook. Given the market cap, the stock is likely to see a positive reaction, estimated between 2% to 8%.
Key Financial Performance
Net Revenue Record net revenue in 2025 of $856 million, a 13% increase versus 2024, and total net revenue of $1.24 billion, representing a 4% increase compared to the prior year. The increase was driven by strong SUBLOCADE net revenue growth and improved commercial execution.
Adjusted EBITDA Adjusted EBITDA grew 20% year-over-year to $428 million in 2025, along with notable margin improvement. This growth was attributed to improved commercial execution and cost management.
Operating Expenses Operating expenses were reduced and will not exceed $450 million in 2026. Non-GAAP operating expenses were $622 million for the full year, down 5% year-over-year, driven by reductions in headcount and footprint consolidations.
SUBLOCADE Net Revenue Total SUBLOCADE net revenue of $856 million for the year increased 13% versus the prior year. The growth was driven by a 7% increase in dispense volume and gross-to-net benefits.
SUBOXONE Film Net Revenue SUBOXONE Film net revenue benefited from continued generic price stability in the U.S., with a gross-to-net benefit of $55 million for the full year.
R&D Expenses Non-GAAP R&D expenses were $80 million for the full year, down 22% year-over-year, due to the reprioritization of pipeline activities and restructuring of the R&D and medical affairs organizations.
Cash Flow Underlying cash flow from operations was over $200 million in 2025, even after paying a $295 million obligation related to the legacy DOJ matter. This payment eliminated a significant future liability for the company.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
SUBLOCADE net revenue: Achieved record net revenue of $856 million in 2025, a 13% increase from 2024. Expected to grow by 8% in 2026, with mid-teens dispense unit growth.
Direct-to-consumer campaign: Launched 'Move Forward in Recovery' campaign in October 2025 to increase awareness of SUBLOCADE. Early indicators show increased patient engagement and awareness.
Long-acting injectable market: SUBLOCADE remains the #1 prescribed long-acting injectable for opioid use disorder. Efforts are ongoing to expand patient access and improve provider adoption.
Operating expenses: Streamlined operations to ensure expenses do not exceed $450 million in 2026. Reduced non-GAAP operating expenses by 5% in 2025.
Adjusted EBITDA: Grew by 20% in 2025 to $428 million. Expected to grow by 30% in 2026, with a 13 percentage point margin improvement.
Financial profile: Paid off $295 million DOJ obligation, reducing liabilities. Ended 2025 with net leverage below 1x and $222 million in cash and investments.
Capital deployment strategy: Announced a $400 million share repurchase program and plans to evaluate business development opportunities for commercial stage assets.
Indivior Action Agenda Phase II: Focused on accelerating SUBLOCADE growth, improving adjusted EBITDA, and creating long-term shareholder value.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Policy Barriers: Several states only allow long-acting injectables under a medical benefit, creating logistical complexity, upfront costs, and administrative burdens for providers. This limits provider adoption and patient access.
Market Utilization Challenges: Long-acting injectables, including SUBLOCADE, remain underutilized despite efforts to improve awareness and access.
Revenue Dependence on SUBLOCADE: The company’s growth heavily relies on SUBLOCADE, making it vulnerable to any market or competitive disruptions affecting this product.
Generic Price Stability Risk: Continued reliance on generic price stability for SUBOXONE Film in the U.S. poses a risk if market conditions change.
Operational Restructuring Costs: Simplification actions, including severance costs and write-offs, incurred $120 million in charges in 2025, with potential ongoing impacts.
Financial Pressure from Legacy Obligations: The company paid $295 million to resolve a legacy DOJ matter, which, while eliminating a liability, impacted cash reserves.
Commercial Channel Productivity: Efforts to improve commercial dispense yield productivity are still in early stages, with progress needed to reach non-commercial channel averages.
Economic and Cash Flow Risks: The company’s financial guidance for 2026 includes a modest decline in total net revenue, primarily due to expected pressure on SUBOXONE Film and other products.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
SUBLOCADE dispense unit growth: Expected to grow in the mid-teens in 2026, an acceleration compared to the 7% growth achieved in 2025.
SUBLOCADE net revenue growth: Projected to grow by 8% at the midpoint of the 2026 guidance range.
Adjusted EBITDA growth: Expected to grow by 30% in 2026, representing a 13 percentage point improvement in adjusted EBITDA margin compared to 2025.
Cash flow from operations: Projected to generate approximately $300 million in 2026.
Capital deployment priorities: Focus on managing debt, executing a $400 million share repurchase program, and evaluating business development opportunities to acquire commercial stage growth drivers.
Total net revenue: Expected to range between $1.125 billion and $1.195 billion in 2026, with a modest decline at the midpoint due to expected U.S. SUBOXONE Film pressure and other factors.
Non-GAAP operating expenses: Projected to range between $430 million and $450 million in 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: The company announced a new $400 million share repurchase program authorized by the Board. This program has a term of up to 18 months and is part of the company's capital deployment strategy to return value to shareholders.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the potential penetration of LAI buprenorphine modalities in the OUD space?
A:The current penetration is at 9%, with significant opportunity for growth. Indivior's research supports potential penetration in the range of 20% to 30%, based on analogs like schizophrenia where penetration is at 30%. The company is committed to educating and activating consumers to increase penetration.
Q:How is Indivior's market share for LAI buprenorphine modalities performing?
A:Indivior's market share has stabilized in the mid-70% range. The company focuses on new patient share, which has been strong, achieving all-time highs in new patient starts.
Q:What are Indivior's plans for capital deployment and business development?
A:Indivior is not looking to acquire commercial assets in the opioid use disorder space. Instead, they aim to establish a new strategic area with commercial-stage assets having peak sales potential of over $200 million, a long runway, and differentiation. They are also focused on shareholder value through share repurchases and addressing expensive debt.
Q:What does Indivior's guidance assume for LAI market growth and market share in 2026?
A:Indivior assumes mid-teens SUBLOCADE growth and expects continued stabilization of market share.
Q:What was the LAI market growth in 2025?
A:The LAI market growth in Q4 2025 was approaching 18%.
Q:What is Indivior's approach to capital allocation between buybacks and M&A?
A:Indivior plans to balance debt servicing, share repurchases, and business development. They have authorized a $400 million share repurchase program and will evaluate opportunities based on business needs and shareholder value.
Q:What is Indivior's perspective on Medicaid funding and its impact on SUBLOCADE growth?
A:Indivior is optimistic about Medicaid funding and bipartisan support for substance use disorder treatment. They believe SUBLOCADE's growth will not be significantly impacted by changes in Medicaid population due to the low current penetration of long-acting injectables.
Q:What is the expected SG&A expense trend for 2026?
A:SG&A expenses are expected to be relatively flat across quarters in 2026, with some skew towards the first three quarters due to the DTC campaign.
Q:How does Indivior view SUBLOCADE's potential to reach $1 billion in sales?
A:Indivior is focused on delivering financial commitments for 2026 and believes SUBLOCADE has significant potential for growth, both commercially and in addressing opioid use disorder.
Q:What therapeutic areas is Indivior considering for new assets?
A:Indivior is not focusing on opioid or substance use disorder for new acquisitions. They are considering other therapeutic areas with commercial-stage assets that meet their business fundamentals.
Q:What is the contribution of the criminal justice system to SUBLOCADE's 2026 guidance?
A:The criminal justice system is seen as a rebased business with growth potential, contributing to the mid-teens growth guidance for SUBLOCADE.
Q:What is the outlook for SUBLOCADE revenues outside the U.S.?
A:SUBLOCADE revenues outside the U.S. are expected to be relatively flat, with growth in Australia and Canada offset by declines in the Nordics.
Q:What is the impact of Phase III decisions on R&D expenses?
A:The 2026 budget includes potential costs for advancing Phase III programs. Decisions will depend on manufacturing feasibility, payer validation, and clinical trial design.
Q:Review of Unclear Management Responses
A:Management avoided providing specific peak penetration projections for LAI buprenorphine modalities, detailed Medicaid funding impacts for 2027, exact DTC spending amounts, and specific timelines or thresholds for SUBLOCADE reaching $1 billion in sales. They also did not provide detailed assumptions for LAI penetration in 2026 or specific revenue expectations for SUBLOCADE outside the U.S.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Accelerate
Action Agenda
Action agenda
Indivior Action
Officer Chief
Phase II
Phase III
Phase Indivior
SUBLOCADE treatment
SUBOXONE Film
acceleration
breakout
campaign
capital deployment
development opportunity
dispense unit
engagement
foundation
injectables
mid teen
model Phase
momentum
payment
people OUD
people use
period
point
policy
profile
provider
record
repurchase program
share repurchase
yield
INDV Transcript
Indivior Pharmaceuticals, Inc. (INDV) Q4 2025 Earnings Call Transcript
Positive2-26
Indivior's earnings call highlights strong financial performance, with SUBLOCADE revenue growth and improved cash flow, despite a significant DOJ payment. Optimistic guidance for 2025 and a focus on shareholder returns through share repurchases are positive indicators. While management avoided some specifics, the overall sentiment in the Q&A was positive, with analysts recognizing growth potential in LAI buprenorphine penetration. The company's strategic focus on new therapeutic areas and operational efficiencies further supports a positive outlook. Given the market cap, the stock is likely to see a positive reaction, estimated between 2% to 8%.
Indivior PLC (INDV) Q3 2025 Earnings Call Transcript
Positive10-30
The company has raised its financial guidance for 2025, indicating strong performance and growth expectations. The Q&A section reveals effective cost management and strategic focus on SUBLOCADE's growth, with positive indicators such as increased dispense growth and prescriber base. Despite some management evasiveness, the overall sentiment is positive, supported by strong financial metrics and optimistic guidance.
Indivior PLC (INDV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral9-8
Indivior PLC (INDV) Q2 2025 Earnings Call Transcript
Unknown8-1
The earnings call presents a mixed picture: modest revenue growth and strong SUBLOCADE performance are offset by execution risks and vague guidance. The Q&A reveals management's strategic focus but lacks specific targets, leading to uncertainty. The stock's market cap suggests modest volatility, aligning with a neutral prediction.
INDV Slides
INDV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
